Bladder Cancer Update: Advances in Treatment and the Role of Early Diagnosis
Bladder cancer (BC) is the tenth most common cancer worldwide, and its associated five-year survival rate declines rapidly (from 96% to 6%) as it progresses from in situ through local invasion, regional spread and finally to distal spread. Thus, early detection and timely therapeutic interventions are crucial to improve outcomes and reduce the burden of disease. Outcomes have been further improved by the integration of recently approved therapies for BC, the utilization of biomarkers to guide treatment plans and the opportunity for eligible patients with BC to enroll in clinical trials. For all treatment plans, effective communication among the health care team is crucial for providing comprehensive care for this condition.
This activity will provide participants with an overview of early BC diagnosis and its impact on survival rates. It will explore recently approved therapies for BC both as standalone treatments and in combination with established therapeutic approaches. Emerging therapies and their potential benefits will be examined, and the value of biomarkers will be discussed. Participants will gain insight into treatment strategies to optimize patient outcomes in BC.
This activity is provided by Optum Health Education.
This activity is supported by an independent education grant from Seagen Inc. and Astellas.
Please ensure you are using the web-browser Chrome and disable any pop-up blocking software. Click here for information on how to enable pop-ups.
This activity is designed to meet the educational needs of case managers, counselors, dietitians, nurses, nurse practitioners, pharmacists, pharmacy technicians, physicians, PAs, psychologists, social workers, therapists and other health care professionals (HCPs) who have an interest in learning about bladder cancer.
At the end of this educational activity, participants should be able to:
- Discuss the demographics of individuals diagnosed with BC and how such demographics impact clinical drug development.
- Identify the most recently approved therapies for BC and how these are being integrated into practices for BC alone and in combination with therapeutic mainstays.
- Review emerging therapies and ongoing clinical trials and how these may benefit individuals with BC.
- Describe the potential role of current and future biomarkers in selecting treatments for individuals with BC.
Matthew D. Galsky, MD, FASCO
Professor of Medicine (Hematology and Medical Oncology
Director of Genitourinary Medical Oncology
Co-Director of the Center of Excellence for Bladder Cancer
Associate Director for Translational Research
Tisch Cancer Institute
Icahn School of Medicine
About the presenter
Dr. Galsky is Professor of Medicine (Hematology and Medical Oncology), Director of Genitourinary Medical Oncology, Co-Director of the Center of Excellence for Bladder Cancer at The Tisch Cancer Institute, and Associate Director for Translational Research at The Tisch Cancer Institute. Dr. Galsky specializes in the care of patients with genitourinary malignancies - bladder, prostate, kidney, and testicular cancers. His research centers on team science-based approaches to dissecting the mechanistic underpinnings of response and resistance to novel bladder cancer therapies with a particular focus on immunotherapeutic approaches.
Elizabeth Albert, MD
Clinical Activity Manager
Optum Health Education
Disclosures of relevant financial relationships
In accordance with the Accreditation Council for Continuing Medical Education's (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, Optum Health Education (OHE) requires all those in control of educational content to disclose their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are defined by the ACCME as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. Individuals must disclose all financial relationships, regardless of the amount, with ineligible companies and regardless of their view of the relevance of the relationship to the education. OHE ensures that the content is independent of commercial bias.
Dr. Galsky has discloses that he has served as a consultant related to immunotherapeutic agents for Abbvie, Alligator Bioscience, Analog Devices, Asieris, AstraZeneca, Basilea, Bicycle Therapeutics, Bristol Myers Squibb, Curtis, Dendreon, Dragonfly, EMD Serono, Fujifilm, Genentech, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis. Numab, Pfizer, Rappta Therapeutics, Seagen, Silverback Therapeutics, UroGen, and Veracyte.
Dr. Albert has no financial relationships to disclose.
All relevant financial relationships have been mitigated.
In support of improving patient care, this activity has been planned and implemented by Optum Health Education. Optum Health Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
Credit designation statements
This activity was planned by and for the health care team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credits for learning and change.
The participant will be awarded up to 1.00 contact hour(s) of credit for attendance and completion of supplemental materials.
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts credit from organizations accredited by the ACCME and ANCC.
This activity is approved for 1.00 contact hour ([0.10] CEU) in states that recognize ACPE.
Attending the full program will earn 1.00 contact hour.
Unique Activity Number(s): JA0007123-0000-23-112-H01-P/T
Optum Health Education designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Academy of Physician Assistants (AAPA) accepts credit from organizations accredited by the ACCME.
The Commission for Case Manager Certification has approved this program for a maximum of 1.00 clock hours for Certified Case Managers (CCM).
Optum Health Education is approved by the American Psychological Association (APA) to offer continuing education for psychologists. Optum Health Education maintains responsibility for this program. 1.00 CE hour.
As a Jointly Accredited Organization, Optum Health Education is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. Optum Health Education maintains responsibility for this course. Social workers completing this course receive 1.00 enduring continuing education credits.
Counselors and/or marriage and family therapists
CA: The Board of Behavioral Sciences has deferred CE course approvals to APA and ASWB for its licensees. See those approvals under Psychologists and Social Workers.
Other States: If your state is not specifically listed, nearly all state Counselor and MFT boards accept either APA or ASWB approval, or are reciprocal with other state licensing board approvals. Check with your board to be sure.
Completion of this RD/DTR profession-specific or IPCE activity awards CPEUs (One IPCE credit=One CPEU).
RD's and DTRs are to select activity type 102 in their Activity Log. Performance indicator selection is at the learner's discretion.
A certificate of attendance will be provided to learners upon completion of activity requirements, enabling participants to register with licensing boards or associations that have not been preapproved for credits. To apply for credit types not listed above, participants should use the procedure established by the specific organization from which they wish to obtain credit.
- 1.00 ACPE - Pharmacists
- 1.00 ACPE - Pharmacy Technicians
- 1.00 AMA - Physicians
- 1.00 ANCC - Nurses
- 1.00 APA - Psychologists
- 1.00 Attendance - General Attendance
- 1.00 CCMC - General - Case Managers
- 1.00 CDR - Dietitians
Fees: There are no fees for participating in or receiving credit for this activity.
Questions: Email firstname.lastname@example.org.